⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allyl Alcohol SCHEMBL3782 | 0.95 | — | — | |
| Allyl Alcohol SCHEMBL1331425 | 0.95 | — | — | |
| Allyl Alcohol SCHEMBL4940557 | 0.95 | — | — | |
| Allyl Alcohol SCHEMBL1332489 | 0.95 | — | — | |
| Allyl Alcohol SCHEMBL4654133 | 0.90 | — | — | |
| Allyl Alcohol SCHEMBL9845385 | 0.90 | — | — | |
| Allyl Alcohol SCHEMBL4601219 | 0.90 | — | — | |
| Allyl Alcohol SCHEMBL565195 | 0.90 | — | — | |
| Allyl Alcohol SCHEMBL4729230 | 0.90 | — | — | |
| Allyl Alcohol SCHEMBL5382706 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316345-B1 | COMPOSITION FOR SECONDARY BATTERY POROUS MEMBRANE, POROUS MEMBRANE FOR SECONDARY BATTERY, AND SECONDARY BATTERY | ZEON CORP (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10601011-B2 | Composition for secondary battery porous membrane, porous membrane for secondary battery, and secondary battery | ZEON CORPORATION (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190263742-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10118881-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3316345-A1 | COMPOSITION FOR SECONDARY-CELL POROUS FILM, SECONDARY-CELL POROUS FILM, AND SECONDARY CELL | Zeon Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9624152-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-8497301-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120225908-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2404890-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402300-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-7812199-B2 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7335799-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | GLAS AMERICAS LLC | 2005-02-24 | — | — | US | disclosed |
| US-3983144-A | Novel 11β-alkyl steroids of the estrane series | AKZONA INCORPORATED (US) | 1976-09-28 | — | — | US | disclosed |